|
|
|
| Value of multiple tumor-associated autoantibodies in the diagnosis of nonsmall cell lung cancer |
| CHEN Mei-ren |
| Department of Laboratory Medicine, Affiliated Hospital of Medical College of Jiaying University, Guangdong Province,Meizhou 514000, China |
|
|
|
|
Abstract Objective To analyze the value of multiple tumor-related autoantibodies in the diagnosis of non-small cell lung cancer (NSCLC). Methods A total of 57 patients with newly diagnosed NSCLC who underwent radical resection of lung cancer in the Affiliated Hospital of Medical College of Jiaying University were selected as the NSCLC group between January 2019 and July 2020. Meanwhile, 52 patients with benign lung diseases (benign group) and 58 healthy people (healthy group) were selected as the control group. Seven tumor-related autoantibodies, including, tumor suppressor gene p53 (p53), protein gene product 9.5 (PGP9.5), sex determining region Y-box2 (SOX2), G antigen 7(GAGE7), tumor antigen (GBU4-5), cancer associated gene (GAGE) and melanoma antigen 1 (MAGE A1) were detected by ELISA. The receiver operating characteristic (ROC) curve was used to analyze the value of above seven tumor-related autoantibodies in the diagnosis of NSCLC. Results The levels of p53, PGP9.5, SOX2, GAGE7, GBU4-5, GAGE and MAGE A1 in the NSCLC group were higher than those in the benign group and the healthy group, and the differences were statistically significant (P＜0.05). The area under curve values of p53, PGP9.5, SOX2, GAGE7, GBU4-5, GAGE,and MAGE A1 alone for diagnosing NSCLC were all larger than 0.6 (P＜0.05), indicating certain diagnostic value. According to the largest Youden index, the cut-off values determined were 1.57 U/ml, 12.92 U/ml, 12.67 U/ml, 14.64 U/ml,8.45 U/ml, 10.65 U/ml, and 7.68 U/ml, respectively. For single diagnosis, the sensitivity of p53 was the highest(91.20%), followed by GAGE (68.40%), and GP 9.5 and GAGE7 (both 59.60%). Conclusion All of the 7 tumor-associated autoantibodies have certain value in the diagnosis of NSCLC.
|
|
|
|
|
|
| [1] |
高映浩，侯恩存，甘川.非小细胞肺癌EGFR-TKI 获得性耐药后治疗策略的研究进展[J].现代肿瘤医学，2018，26（14）：151-155.
|
| [2] |
霍云丽，郭子建.肺癌自身抗体在肿瘤早期诊断和治疗中的临床应用进展[J].标记免疫分析与临床，2019，26（5）：887-891.
|
| [3] |
Goldstraw P，Chansky K，Crowley J，et al.The IASLC Lung Cancer Staging Project：Proposals for Revision of the TNM Stage Groupings in the Forthcoming （Eighth）Edition of the TNM Classification for Lung Cancer[J].J Thorac Oncol，2016，11（1）：39-51.
|
| [4] |
刘苗苗，南岩东，陈艳丽，等.血清肿瘤标志物和自身抗体与肺癌患者临床病理特征的相关性研究[J].中华肺部疾病杂志（电子版），2018，11（2）：176-181.
|
| [5] |
王卓，张玉宇，张兰广，等.非小细胞肺癌脑转移的治疗进展[J].中国老年学杂志，2016，36（4）：232-236.
|
| [6] |
裴艳丽，许建名，徐冰凌，等.肺癌危险因素及早期筛查方法研究进展[J].癌症进展，2020，18（10）：7-10.
|
| [7] |
蓝燚锋，叶艺先，蔡宇超.计算机辅助检测系统（CAD）在16 层CT 低剂量肺癌筛查肺结节检出中的应用价值[J].中国医药指南，2019，17（23）：5-7.
|
| [8] |
高敏，刘若男，柯张延，等.1TAP，Hsp90α 联合肺癌肿瘤标志物对小细胞肺癌诊断价值[J].临床肺科杂志，2020，25（1）：88-92.
|
| [9] |
蒋建文，刘忠.自身抗体检测在肺癌早期诊断中的价值[J].中华健康管理学杂志，2019，13（5）：432-435.
|
| [10] |
齐宝库.非小细胞肺癌早期诊断中应用CT 检测联合多种肿瘤标志物的临床意义探究[J].世界最新医学信息文摘，2018，18（53）：160-163.
|
| [11] |
杨庭义，常宁，韩志萍，等.肿瘤相关自身抗体在肺癌筛查和早期诊断领域的研究进展[J].国际呼吸杂志，2020，40（4）：307-312.
|
| [12] |
王宇璐，陆乘俊，李玉涛，等.血清七种自身抗体联合癌胚抗原和糖类抗原199 检测对肺癌的诊断价值[J].临床误诊误治，2018，31（5）：96-100.
|
| [13] |
赵娟，刘宁，郭婧婧，等.7 种肿瘤相关抗原自身抗体检测在肺癌诊断中的意义[J].临床检验杂志，2017，35（5）：326-329.
|
| [14] |
贾金芳，黄静，朱晓莉.肿瘤相关自身抗体对恶性肺结节的诊断价值[J].中国肿瘤临床，2020，47（6）：271-276.
|
| [15] |
陆柳，丁梦蕾，成宇，等.七项肿瘤相关自身抗体检测联用在非小细胞肺癌辅助诊断中的临床价值[J].中华检验医学杂志，2019，42（9）：768-775.
|
| [16] |
杨鑫，闫中义，郭向前，等.自身抗体在鉴别肺小结节中的作用[J].河南大学学报（医学版），2019，38（1）：53-57.
|
| [17] |
吴昱冶，黄美玲.晚期肺癌患者血清肿瘤标志物与凝血功能变化的临床研究[J].中国医药科学，2019，9（16）：202-204.
|
| [18] |
赵诤，李海军，陈效琴，等.晚期非小细胞肺癌患者TKI靶向治疗与肿瘤组织EGFR 基因突变的关系[J].中国医药导报，2019，16（10）：162-165.
|
|
|
|
